Vertex Takes Early Lead In HCV Protease Inhibitor Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Incivek, launched in May, already has posted sales of $74.5 million, while Merck's competing Victrelis has tallied $21 million in sales so far.
You may also be interested in...
Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.
Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.
Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.